Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within a few weeks in most patients, the most severe forms result in multi-organ dysfunction and are associated with a high mortality rate (>80%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly as drugs have now proven to be effective and licensed for its treatment. Unfortunately, current criteria lack sensitivity and specificity, making early identification and severity assessment of SOS/VOD difficult. The aim of this work is to propose a new definition for diagnosis, and a severity-grading system for SOS/VOD in adult patients, on behalf of the European Society for Blood and Marrow Transplantation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935979 | PMC |
| http://dx.doi.org/10.1038/bmt.2016.130 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Various Hydrogel Types as a Potential In Vitro Angiogenesis Model.
Gels
December 2024
Biointerface Laboratory, Helmholtz-Institut for Biomedical Engineering, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany.
Angiogenesis, the formation of new blood vessels, is a fundamental process in both physiological repair mechanisms and pathological conditions, including cancer and chronic inflammation. Hydrogels are commonly used as in vitro models to mimic the extracellular matrix (ECM) and support endothelial cell behavior during angiogenesis. Mesenchymal stem cells further augment cell and tissue growth and are therefore widely used in regenerative medicine.
View Article and Find Full Text PDFDrug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives.
Arch Toxicol
December 2024
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Hepatic sinusoidal obstruction syndrome (HSOS) has gained recognition as a rare form of drug-induced liver injury (DILI) in recent years. Although extensively studied in the context of hematopoietic stem cell transplantation (HSCT), the applicability of this knowledge to drug-induced HSOS remains limited due to distinct etiological factors. The primary causes of drug-induced HSOS include the ingestion of pyrrolizidine alkaloid (PA)-containing plants, as well as the use of chemotherapeutic agents and immunosuppressive drugs.
View Article and Find Full Text PDFBusulfan conditioning and prognostic impact of jaundice in late-onset sinusoidal obstruction syndrome following allogeneic hematopoietic cell transplantation.
Bone Marrow Transplant
December 2024
Department of Hematology, Toranomon Hospital, Tokyo, Japan.
Effects of Congestion in Human Lung Investigated Using Dual-Scale Porous Medium Models.
Int J Numer Method Biomed Eng
January 2025
Heat Transfer and Thermal Power Laboratory, Department of Mechanical Engineering, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India.
Chronic obstructive pulmonary disease (COPD) is a primary chronic respiratory disease associated with pulmonary congestion that restricts airflow and thereby affects the exchange of gases between the alveoli and the blood capillaries in the lungs. Dual scale-global and local-porous medium models have been developed and reported in this work, to study the effects of air-side congestion on the blood-oxygen content in the alveolar region of the human lung. The human lung is model as a global, equivalent, heterogeneous porous medium comprising three zones with distinct permeabilities related to their progressively complex branching structure.
View Article and Find Full Text PDFCPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
Leuk Lymphoma
December 2024
Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.
In this multicenter phase Ib trial, we investigated the combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory acute myeloid leukemia (AML). Cohort A received CPX-351 plus a single dose of GO, while cohort B received two doses of GO. Thirteen participants received investigational treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!